IdentifAI Genetics · raw details

Noninvasive Prenatal Testing for Genetic Disorders · Rosh Haayin · Founded 2020

active Seed ← back to profile

Highlights

IIA supported (ever)1 patentProfile claimed by owner

About

Noninvasive Prenatal Testing for Genetic Disorders

Identifai Genetics is developing a noninvasive prenatal test for the early detection of single-gene disorders. Using a simple first-trimester maternal blood test to access the entire embryonic genome, Identifai can perform a comprehensive analysis capable of detecting every single-point mutation, insertion-deletion, and structural variation in order to identify severe genetic disorders. Identifais core suite of algorithms, the Hoobari paradigm, is a patent-pending proprietary methodology developed for five years at Tel Aviv University. The technology has demonstrated high accuracy in detecting a wide variety of mutations in real-life cases, and the company is planning to launch clinical studies. Identifai Genetics is dedicated to providing solutions that will enable safe pregnancies for all families, everywhere.

Identity

NameIdentifAI Genetics
Slugidentifai-genetics
Type / kindstartup
Source _idagxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4K-E3coKDA

Status

Statusactive
Last update2026-05-17

Location

HQ country codeIL
HQ region/districtCenter District
HQ cityRosh Haayin
HQ addressHaMelacha Street 22, Rosh Haayin, Israel

Web & social

Websitehttps://identifai-genetics.com/
Careers pagehttps://identifai-genetics.com/careers
LinkedInhttps://www.linkedin.com/company/73265414

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Technologies
BiologicalsGenesArtificial IntelligenceMachine LearningDeep Learning
Target customers
Healthcare & Life SciencesHealthcareInsurance CompaniesLaboratoriesPatientsProvidersLife SciencesBiotechnology
Business models
B2B2CB2B
Tags
femtechpregnancygeneticsmachine-learningdeep-learningdiagnosticsartificial-intelligencewomen-healthbiotechnologygenetic-disordersnon-invasivebabiesblood-testearly-detectionhealthcare-providerswomenpharmaceuticals

Funding

Total raised$9.3M
Current stageSeed

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}